专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JPH07101874A REPAIRING AND THERAPEUTIC AGENT FOR BONE 失效
公开(公告)号：JPH07101874A
公开(公告)日：1995-04-18
申请号：JP28000593
申请日：1993-10-04
申请人： SUNTORY LTD
发明人： MATSUI MASASHI , ISHIDA NOBUHIRO , NAKAZATO HIROSHI , KANAI SADA
IPC分类号： A61K47/42 , A61K6/884 , A61K38/00 , A61L27/00 , A61P43/00 , A61K6/08
摘要： PURPOSE:To obtain a repairing and therapeutic agent for bones containing a bone morphogenetic factor as an active ingredient. CONSTITUTION:The characteristic of this repairing and therapeutic agent for bones comprises a bone morphogenetic factor as an active ingredient, fibrin as a carrier and further >=4mug bone morphogenetic protein content based on 1ml fibrin paste gel.

2. 发明专利

JPH0741421A PREVENTIVE AGENT OR IMPROVER FOR MEDICAL SYMPTOM USING LEUKOTRIENE B4 (LTB4) 失效
公开(公告)号：JPH0741421A
公开(公告)日：1995-02-10
申请号：JP11280094
申请日：1994-05-26
申请人： SUNTORY LTD
发明人： AKIMOTO KENGO , KAWASHIMA HIROSHI , YOSHIMURA SATOMICHI , MATSUI MASASHI , HAMAZAKI TOMOHITO , SAWAZAKI SHIGEKI , NAKAMURA NORIO
IPC分类号： A23L1/30 , A23L33/00 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/23 , A61K31/231 , A61K31/232 , A61P29/00 , A61P37/08 , C07C57/03 , C07C57/12 , C07C69/587
摘要： PURPOSE:To provide preventive agent or improved for medical symptoms, esp. effective as an anti-inflammatory agent or anti-allergic agent, also relatively low in side effects, and applicable to chronic symptoms. CONSTITUTION:The preventive agent or improver containing, as active ingredient, an omega 9-series unsaturated fatty acid, pref. 6,9-octadecadienoic acid, 8,11-eicosadienoic acid or 5,8,11-eicosatrienoic acid. The dose of the fatty acid when to be used as a medicine is 1-1000 (esp. 1-200)mg a day per adult for oral administration, or 0.1-100 (esp. 0.1-20)mg a day per adult for parenteral administration. This fatty acid can be incorporated in food/beverage stocks (in particular, such stocks intrinsically virtually free from this fatty acid) and taken in the form of health foods or functional foods.

3. 发明专利

JPH06107695A NOVEL HUMAN BLOOD CELL-RELATED ANTIGEN AND MONOCLONAL ANTIBODY RECOGNIZING THE SAME 失效
公开(公告)号：JPH06107695A
公开(公告)日：1994-04-19
申请号：JP4946993
申请日：1993-03-10
申请人： SUNTORY LTD , TAGAWA SHINICHI
发明人： KITANI TERUO , AOZASA KATSUYUKI , TAGAWA SHINICHI , SHIBANO MASARU , MIZUKI MASAO , MATSUI MASASHI , NAKANISHI TOSHIHIRO
IPC分类号： C07K16/00 , C07K14/435 , C07K19/00 , C12N15/02 , C12N15/06 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/535 , G01N33/577 , C07K15/06
摘要： PURPOSE:To provide a monoclonal antibody enabling the sure diagnosis and therapy of LGL leukemia and pure red cell aplacia and further enabling to detect an antigen in a paraffin-embedded tissue slice. CONSTITUTION:The novel monoclonal antibody is obtained by culturing a hybridoma cell line which is produced by fusing a myeloma-originated cell with the splenic cell of a mammalian sensitized with an antigen comprising a granular large lymphocytic leukemia cell having a natural killer activity; and the human blood cell-relating antigen is recognized with the antibody.

4. 发明专利

JPH06340555A PULP-CAPPING AGENT ENABLING FORMATION OF DENTINE 失效
公开(公告)号：JPH06340555A
公开(公告)日：1994-12-13
申请号：JP16829793
申请日：1993-06-02
申请人： SUNTORY LTD
发明人： NAKAJIMA MISAKO , NAGASAWA HISASHI , MATSUI MASASHI , NAKAZATO HIROSHI
IPC分类号： A61K6/00 , A61K47/42
摘要： PURPOSE:To obtain a dental pulp-capping agent used for therapies of dental caries, especially for the repairing therapy of teeth, utilizing the biological reactions of bone-forming proteins, and having a dentine-regenerating ability on the therapies. CONSTITUTION:This dental pulp-capping agent enabling the formation of dentine contains a purified bone-forming protein as an active ingredient and, if necessary, a carrier having biodegradability, tissue compatibility and sustained releasability. When the pulp-capping agent is charged on the dental pulp-cut surface of a tooth cavity after the removal of a carious part, a large volume of dentine is formed on the dental pulp-cut surface to perfectly protect the left dental pulp, thereby enabling to provide a remarkable therapeutic method capable of keeping the original functions of teeth.

5. 发明专利

JPS5829737A NOVEL 9-MEMBERED RING COMPOUND 失效
公开(公告)号：JPS5829737A
公开(公告)日：1983-02-22
申请号：JP12836981
申请日：1981-08-15
申请人： SUNTORY LTD
发明人： ENDOU MAMORU , NAKAGAWA TADASHI , NAKANISHI TOSHIHIRO , MATSUI MASASHI , HAMAMOTO YOSHIHIRO , TAKEYAMA KIYOUKO
IPC分类号： A61K31/12 , A61P35/00 , C07C45/00 , C07C49/607 , C07C67/00
摘要： NEW MATERIAL:Clavularin A shown by the formula. USE:To be expected as a carcinostatic agent. PROCESS:Frozen and stored Clavularia viridis Quoy & Gaimard is stirred and extracted twice with methanol, the residue is extracted with methylene chloride, and both the extracted solutions are concentrated. The prepared concentrated residue is dissolved in methylene chloride again, impurities are removed, and a filtrate is concentrated. The concentrated filtrate is adsorbed on a silica gel column, eluted with chloroform-methanol, a fraction having a cell toxicity is collected, the fraction is adsorbed on a gel filtration column, and eluted. The fraction having the cell toxicity is adsorbed on a silica gel thin layer chromatography plate, an ultraviolet-absorbing band showing a Rf of about 0.6 when it is developed with chloroform-methanol is eluted, and concentrated to give raw Clavularin A. The raw Clavularin A is adsorbed on the silica gel thin layer chromatography plate, developed with n-hexane-ethyl acetate to give the desired high-purity substance purer than a band having a Rf of about 0.4.

6. 发明专利

JPS59132885A Novel cell line 失效
标题翻译：新细胞线
公开(公告)号：JPS59132885A
公开(公告)日：1984-07-31
申请号：JP774483
申请日：1983-01-20
申请人： Suntory Ltd
发明人： NAKANISHI TOSHIHIRO , MATSUI MASASHI , MIURA TAKEHISA , FUKUDA YOSHIAKI , NOGUCHI TERUHISA
IPC分类号： C12N15/02 , A61K39/395 , C07K14/52 , C07K14/57 , C12N5/10 , C12N5/16 , C12P21/08
CPC分类号： A61K39/395 , C07K14/52 , C07K14/57 , C12N5/163
摘要： PURPOSE: To obtain a cell line for preparing hybridoma derived by mutation from tumor cells other than a tumor cell derived from marrow cell.
CONSTITUTION: A cancerous cell is irradiated with ultraviolet rays or provided with a mutagen such as ethylmethanesulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, etc. in a proper dose or amount depending upon its kind, the cell is transferred to a medium containing 8-azaguanidine, to develop a strain resistant to 8-azaguanidine. The use of HAT selection is then examined. The cell is cultivated, the medium is removed by centrifugation, the cell is washed with a HAT medium, and transferred to the same HAT medium. It is observed for several days, and life or death is judged.
COPYRIGHT: (C)1984,JPO&Japio
摘要翻译：目的：获得一种细胞系，用于制备源自骨髓细胞的肿瘤细胞以外的肿瘤细胞产生的杂交瘤。构成：根据其种类，以适当的剂量或量将紫外线照射或设置有甲基磺酸乙酯，N-甲基-N'-硝基-N-亚硝基胍等诱变剂，将细胞转移至一种含有8-氮杂鸟嘌呤的培养基，开发出抗8-氮杂鸟嘌呤的菌株。然后检查使用HAT选择。培养细胞，通过离心除去培养基，用HAT培养基洗涤细胞，并转移到相同的HAT培养基中。观察了几天，判断生死攸关。

7. 发明专利

JPS595193A Cyclic peptide 失效
标题翻译：循环肽
公开(公告)号：JPS595193A
公开(公告)日：1984-01-12
申请号：JP11372682
申请日：1982-06-30
申请人： Suntory Ltd
发明人： HAMAMOTO YOSHIHIRO , ENDOU MAMORU , NAKAGAWA TADASHI , NAKANISHI TOSHIHIRO , MATSUI MASASHI
IPC分类号： C07D513/22 , A61K31/425 , A61P35/00
摘要： NEW MATERIAL:The cyclic peptide of the formula.
USE: Carcinostatic agent.
PREPARATION: For example, a kind of ascidian living in Queensland of Australia is freeze dried and made into powder. The powder is extracted with ethanol several times and the extract is evaporated by splitting off the ethanol under reduced pressure. Then, the resultant solid product is purified by column chromatography or silica-gel chromatography to obtain the cyclic peptide of the formula from the cytotoxic fraction.
COPYRIGHT: (C)1984,JPO&Japio
摘要翻译：新材料：式的环肽。用途：致癌剂。准备：例如，居住在澳大利亚昆士兰州的一种天竺葵被冷冻干燥并粉碎。粉末用乙醇萃取数次，减压蒸馏除去乙醚。然后，通过柱色谱或硅胶色谱法纯化所得固体产物，从细胞毒性级分获得式的环状肽。

8. 发明专利

JPH11335365A CYTOKININ PRODUCTION INHIBITOR 失效
公开(公告)号：JPH11335365A
公开(公告)日：1999-12-07
申请号：JP10998299
申请日：1999-04-16
申请人： TERAJEN DISCOVERY INC , SUNTORY LTD
发明人： HAYES MARTIN ALISTAIR , HARDICK DAVID JAMES , TANG JENNY SEUKGIN , RYDER HAMISH , FOLKES ADRIAN , MATSUI MASASHI , TATSUOKA TOSHIO
IPC分类号： A61K31/00 , A61K31/35 , A61K31/351 , A61P1/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P29/00 , A61P43/00 , C07D309/32
摘要： PROBLEM TO BE SOLVED: To obtain a cytokinin production inhibitor. SOLUTION: This compound is shown by formula I [a direct bond (a) is a broken line; X is O or NH; R is a group of the formula ArCH2 (Ar is an aryl), a group of the formula R OCH2 (R is a 1-6C alkyl) or the like] such as [(2S,3R)-dihydro-6-oxo-(2E-prop-1-enyl-2H-pyran-3-yl)]benzoate. The compound of formula I is obtained, for example, by esterifying a compound of formula II or a compound of substitute III with a compound of the formula R -COOH (R is a 2-20C alkyl or the like). The compound of formula I can be used for treating immune inflammatory state such as chronic rheumatoid arthritis, osteoarthritis, septic shock, atherosclerosis, inflammatory intestinal disease, clone diseases, etc.

9. 发明专利

JPH0679553B2 失效
公开(公告)号：JPH0679553B2
公开(公告)日：1994-10-12
申请号：JP774583
申请日：1983-01-20
申请人： SUNTORY LTD
发明人： NAKANISHI TOSHIHIRO , MATSUI MASASHI , MIURA TAKEHISA , FUKUDA YOSHIAKI , NOGUCHI TERUHISA
IPC分类号： C12N15/02 , C12N5/00 , C12N5/10 , C12N5/28 , C12N15/00 , C12N15/08 , C12P21/00 , C12P21/08 , C12R1/91

10. 发明专利

JPS61148199A MONOCLONAL ANTIBODY AGAINST TRACE ANTIGEN 失效
公开(公告)号：JPS61148199A
公开(公告)日：1986-07-05
申请号：JP21774185
申请日：1985-09-30
申请人： SUNTORY LTD
发明人： MATSUI MASASHI , SORUDANO FUEROONE
IPC分类号： G01N33/574 , A61K39/395 , C07K14/005 , C07K14/195 , C07K16/00 , C07K16/30 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/577
摘要： PURPOSE:To obtain the titled antibody capable of specifically recognizing malignant tumor cell, by culturing a hybridoma cell line derived from a cell originated from myeloma and a spleen cell of an animal sensitized with a specific tumor cell as antigen. CONSTITUTION:A tumor cell treated with cytokine or lymphokine (e.g., gamma-type interferon) is used as an antigen to sensitize an animal (e.g. mouse) (e.g. by peritoneal infusion, 3 times on every 10 days). The spleen is extracted aseptically from the animal to obtain the spleen cell. A cell originated from myeloma (e.g. mouse myeloma cell) is treated together with the above spleen cell in a medium containing polyethylene glycol, 1,000 to effect the cell fusion, and the fused cell is cultured and screened to obtain a hybridoma cell line. The positive clone is subcloned by critical dilution method to obtain a monoclonal cell, which is cultured to obtain a monoclonal antibody.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式